{"id":1594,"date":"2018-10-29T12:10:50","date_gmt":"2018-10-29T12:10:50","guid":{"rendered":"http:\/\/bibliography.nanobiotix.com\/?p=1594"},"modified":"2022-05-24T16:48:23","modified_gmt":"2022-05-24T15:48:23","slug":"2018-esmo-nbtxr3-in-hcc-and-liver-metastasis","status":"publish","type":"post","link":"https:\/\/bibliography.nanobiotix.com\/fr\/2018-esmo-nbtxr3-in-hcc-and-liver-metastasis\/","title":{"rendered":"2018 \u2013 ESMO \u2013 NBTXR3 in HCC and Liver Metastasis"},"content":{"rendered":"

[vc_row padding_top=\u00a0\u00bb0″ padding_bottom=\u00a0\u00bb0″ section_container_layout=\u00a0\u00bbfull-width\u00a0\u00bb remove_horizontal_padding=\u00a0\u00bbyes\u00a0\u00bb module_type=\u00a0\u00bbbg-color\u00a0\u00bb gutter_size=\u00a0\u00bbyes\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb bg_color=\u00a0\u00bb#28282e\u00a0\u00bb][vc_column][vc_row_inner padding_top=\u00a0\u00bb0″ padding_bottom=\u00a0\u00bb0″ gutter_size=\u00a0\u00bbyes\u00a0\u00bb equal_height=\u00a0\u00bbyes\u00a0\u00bb][vc_column_inner column_paddings=\u00a0\u00bb105″ column_position_vertical=\u00a0\u00bbmiddle\u00a0\u00bb column_min_height=\u00a0\u00bb700″ column_min_height_sm=\u00a0\u00bb400″ column_min_height_xs=\u00a0\u00bb350″ module_type=\u00a0\u00bbbg-image\u00a0\u00bb bg_image=\u00a0\u00bb99″ mask_fx=\u00a0\u00bbyes-mask\u00a0\u00bb mask_color_mode=\u00a0\u00bbpalette\u00a0\u00bb mask_bg_color_palette=\u00a0\u00bbmain-mask\u00a0\u00bb animation_fx=\u00a0\u00bbyes-animation\u00a0\u00bb animation_delay=\u00a0\u00bb200″ animation_offset_scroll_down=\u00a0\u00bb90″ width=\u00a0\u00bb1\/2″ animation_in=\u00a0\u00bbfadeInUp\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][az_box_icons box_icon_title=\u00a0\u00bbAuthors\u00a0\u00bb box_icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_visibility=\u00a0\u00bbyes-icon\u00a0\u00bb icon_type=\u00a0\u00bbfont\u00a0\u00bb icon=\u00a0\u00bbfa fa-edit\u00a0\u00bb icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_size=\u00a0\u00bb50″ box_icon_color=\u00a0\u00bb#ffffff\u00a0\u00bb icon_color=\u00a0\u00bb#ffffff\u00a0\u00bb]Chajon E.1<\/span>, Pracht M.1<\/span>, de Baere T.2<\/span>, Nguyen F.2<\/span>, Bronowicki J.-P.3<\/span>, Vendrely V.4<\/span>, Baumann A.-S.5<\/span>, Crois\u00e9-Laurent V.3<\/span>, Rio E.6<\/span>, Rolland Y.1<\/span>, Le Sourd S.1<\/span>, Gustin P.2<\/span>, Perret C.6<\/span>, Mornex F.7<\/span>, Peiffert D.5<\/span>, Merle P.7<\/span>, Deutsch E.2<\/span>
\n
\n1 \u2013 Radiation Oncology, Centre Eugene \u2013 Marquis, Rennes, FR
\n2 \u2013 Radiation oncology, Institut Gustave Roussy, Villejuif, FR
\n3 \u2013 Hepatology and Gastroenterology, H\u00f4pital de Brabois, Vandoeuvre Les Nancy, FR
\n4 \u2013 Radiotherapy, Groupe Hospitalier Sud \u2013 H\u00f4pital Haut-L\u00e9v\u00eaque, Pessac, FR
\n5 \u2013 Radiotherapy, Institut de Canc\u00e9rologie de Lorraine, Nancy, FR
\n6 \u2013 Radiotherapy, Institut de canc\u00e9rologie de l’Ouest, Nantes, FR
\n7 \u2013 Hepatology and Gastroenterology, Centre Hospitalier de la Croix Rousse, Lyon, FR
\n<\/span>[\/az_box_icons][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][\/vc_column_inner][vc_column_inner column_paddings=\u00a0\u00bb105″ column_position_vertical=\u00a0\u00bbmiddle\u00a0\u00bb module_type=\u00a0\u00bbbg-color\u00a0\u00bb animation_fx=\u00a0\u00bbyes-animation\u00a0\u00bb animation_delay=\u00a0\u00bb300″ animation_offset_scroll_down=\u00a0\u00bb90″ width=\u00a0\u00bb1\/2″ bg_color=\u00a0\u00bb#ffffff\u00a0\u00bb animation_in=\u00a0\u00bbfadeInUp\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][az_box_icons box_icon_title=\u00a0\u00bbSummary\u00a0\u00bb icon_visibility=\u00a0\u00bbyes-icon\u00a0\u00bb icon_type=\u00a0\u00bbfont\u00a0\u00bb icon=\u00a0\u00bbaz-icon az-icon-layers2″ icon_color_mode=\u00a0\u00bbon-the-fly\u00a0\u00bb icon_color=\u00a0\u00bb#28282e\u00a0\u00bb icon_size=\u00a0\u00bb50″]For patients (pts<\/em>) with hepatocellular carcinoma (HCC<\/em>) or liver metastasis (liver mets<\/em>), stereotactic body radiation therapy (SBRT<\/em>) is a well-tolerated option. Yet, the risk of injury to normal tissues limits the ability to efficiently sterilize tumor cells. Thus, hafnium oxide nanoparticles, NBXTR3, were developed, which increase the interaction of radiotherapy energy dose deposition within tumor cells when activated by an ionizing energy source like SBRT<\/em>. NBTXR3 innovative approach does not engage liver function, is characterized by a single injection and fits with radiotherapy standards with no change in pts treatment protocol or equipment occupancy.<\/p>\n

NBTXR3 is currently evaluated in this population in a phase I\/II clinical trial. So far, 13 pts are enrolled. Dose levels are completed at 10% (6 pts) and 15% (4 pts) and currently enrolling at 22% (3 pts). Up to date, no early DLTs and no adverse events related to NBTXR3 were observed. In 9 evaluable pts, the investigator mRECIST assessment on target lesions resulted with the following best observed response: 3 complete responses, 3 partial responses, 1 stable disease and 2 progressive disease. In the same pts, NBTXR3 did not present leakage and did not affect liver function.<\/p>\n

NBTXR3 activated by SBRT<\/em> currently reveal an encouraging safety profile with a favorable efficacy in a vulnerable population with two different liver affections. These outcomes were the result of a complex multidisciplinary cooperation of different medical expertise from different centers.[\/az_box_icons][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb responsive_lg=\u00a0\u00bbhidden\u00a0\u00bb responsive_md=\u00a0\u00bbhidden\u00a0\u00bb][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":"

For patients (pts) with hepatocellular carcinoma (HCC) or liver metastasis (liver mets), stereotactic body radiation therapy (SBRT) is a well-tolerated option. Yet, the risk of injury to normal tissues limits the ability to efficiently sterilize tumor cells. Thus, hafnium oxide nanoparticles, NBXTR3, were developed, which increase the interaction of radiotherapy energy dose deposition within tumor cells when activated by an ionizing energy source like SBRT. [\u2026]<\/p>\n","protected":false},"author":1,"featured_media":1590,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[182,183,669,668],"tags":[196,491,463,342,333,483],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/1594"}],"collection":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/comments?post=1594"}],"version-history":[{"count":1,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/1594\/revisions"}],"predecessor-version":[{"id":1595,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/posts\/1594\/revisions\/1595"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/media\/1590"}],"wp:attachment":[{"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/media?parent=1594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/categories?post=1594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bibliography.nanobiotix.com\/fr\/wp-json\/wp\/v2\/tags?post=1594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}